These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14534332)

  • 1. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 2. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
    N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of protein repair therapy in the treatment of cystic fibrosis.
    Rubenstein RC; Zeitlin PL
    Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
    Kerem E
    Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis.
    Hamilton JW
    Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605
    [No Abstract]   [Full Text] [Related]  

  • 9. Tobramycin is a suppressor of premature termination codons.
    Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M
    J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From the laboratory to the clinic: CFTR and the therapeutic options for cystic fibrosis].
    Mayol J; Alvarez de Arcaya Vicente A; Arbeo Escolar AM; Peña Soria MJ; Alvarez Fernández-Represa J
    An Med Interna; 2000 Feb; 17(2):92-8. PubMed ID: 10829466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation specific therapy in CF.
    Kerem E
    Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in cystic fibrosis therapies.
    Rowe SM; Clancy JP
    Curr Opin Pediatr; 2006 Dec; 18(6):604-13. PubMed ID: 17099358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
    Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
    Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies for cystic fibrosis lung disease.
    Grasemann H; Ratjen F
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):653-9. PubMed ID: 20812885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis: basic science.
    McAuley DF; Elborn JS
    Paediatr Respir Rev; 2000 Jun; 1(2):93-100. PubMed ID: 12531100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protein repair therapy in cystic fibrosis].
    Clément A; Tamalet A; Fauroux B; Epaud R
    Rev Prat; 2003 Jan; 53(2):163-6. PubMed ID: 12664848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From gene to disease; from defective chloride ion transport to cystic fibrosis].
    Scheffer H; van den Ouweland AM; Veeze HJ
    Ned Tijdschr Geneeskd; 2001 Apr; 145(14):686-7. PubMed ID: 11530706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New therapeutic approaches in cystic fibrosis].
    Vestner A; Schrepfer B; Kockler J; Mohr F; Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2008; 37(5):354-5. PubMed ID: 18729285
    [No Abstract]   [Full Text] [Related]  

  • 19. Gentamicin and CFTR.
    Kida Y
    N Engl J Med; 2003 Dec; 349(26):2570. PubMed ID: 14695425
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel human pathological mutations. Gene symbol: CFTR. Disease: cystic fibrosis.
    Farra C; Medawar R; Cabet F; Mroueh S; Souaid M; Hourani H; Mounsef C; Ashkar H; Awwad J
    Hum Genet; 2007 Dec; 122(5):553. PubMed ID: 18383592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.